Premium
N1‐methylnicotinamide (MNAM) as a guardian of cardiovascular system
Author(s) -
Nejabati Hamid Reza,
Mihanfar Aynaz,
Pezeshkian Masoud,
Fattahi Amir,
latifi Zeinab,
Safaie Naser,
Valiloo Mohammad,
Jodati Ahmad Reza,
Nouri Mohammad
Publication year - 2018
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.26636
Subject(s) - prostacyclin , vasoprotective , nitric oxide , coronary artery disease , nicotinamide , chemistry , medicine , cardiology , biochemistry , enzyme
Atherosclerosis is identified as the formation of atherosclerotic plaques, which could initiate the formation of a blood clot in which its growth to coronary artery can lead to a heart attack. N‐methyltransferase (NNMT) is an enzyme that converts the NAM (nicotinamide) to its methylated form, N1‐methylnicotinamide (MNAM). Higher levels of MNAM have been reported in cases with coronary artery disease (CAD). Further, MNAM increases endothelial prostacyclin (PGI2) and nitric oxide (NO) and thereby causes vasorelaxation. The vasoprotective, anti‐inflammatory and anti‐thrombotic roles of MNAM have been well documented; however, the exact underlying mechanisms remain to be clarified. Due to potential role of MNAM in the formation of lipid droplets (LDs), it might exert its function in coordination with lipids, and their targets. In this study, we summarized the roles of MNAM in cardiovascular system and highlighted its possible mode of actions.